![]() The company has raised a total of $82 million from private financings to date. Ansa is solving current industry bottlenecks associated with synthesizing complex DNA sequences that are difficult to obtain from existing DNA synthesis providers.ĮMERYVILLE, Calif.–( BUSINESS WIRE)– Ansa Biotechnologies today announced it has closed an oversubscribed Series A financing round of $68 million led by Northpond Ventures, with participation from new investors RA Capital, Blue Water Life Science Advisors, Altitude Life Science Ventures, Fiscus Ventures, PEAK6 Strategic Capital, Carbon Silicon Ventures, Codon Capital, and existing investors Mubadala Capital, Humboldt Fund, Fifty Years, and Horizons Ventures.Funding will advance next-generation technology platform, expand R&D and manufacturing facilities, grow multidisciplinary team, and launch DNA synthesis service.Ansa’s next-generation enzymatic DNA synthesis technology will dramatically accelerate innovation across every industry enabled by synthetic DNA from biologic drugs to biomanufacturing, and DNA-based data storage.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |